[Toxicogenetics of antiretroviral treatment (1): lipodystrophy, metabolic perturbations and atherosclerosis].

Among the adverse effects attributed to antiretroviral therapy, one of the most striking is probably the appearance of the lipodystrophy syndrome and its associated metabolic derangements, given its potential long-term effect as a cardiovascular risk factor. Since not all patients who receive antiretroviral drugs experience these adverse effects, a host genetic predisposition has been postulated. However, currently available data on this issue is inconclusive and preliminary.

[Pharmacogenetics of antiretroviral therapy 2008: toward personalized treatment?].

The degree of immune restoration in HIV-1-infected patients receiving the same antiretroviral regimen and achieving sustained virologic suppression is highly variable. Equally, not all persons receiving antiretroviral drugs experience adverse effects. Consequently, there seems to be wide interindividual variability in treatment response and toxicity due to antiretroviral therapy.